Literature DB >> 18674845

Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.

Jean E Revuz1, Florence Canoui-Poitrine, Pierre Wolkenstein, Cedric Viallette, Germaine Gabison, Florence Pouget, Florence Poli, Ousmane Faye, Jean Claude Roujeau, Genevieve Bonnelye, Jean Jacques Grob, Sylvie Bastuji-Garin.   

Abstract

BACKGROUND: Conflicting opinions have been reported regarding the epidemiology of hidradenitis suppurativa.
OBJECTIVE: We sought to evaluate the prevalence of hidradenitis suppurativa and to identify associated factors.
METHODOLOGY: Prevalence was evaluated using a representative sample of the French population (n=10,000). Associated risk factors were assessed using two case-control studies, one population-based with 67 self-reported patients and 200 control subjects, and the other clinic-based with 302 medically assessed patients and 906 control subjects.
RESULTS: The prevalence was 1% of the French population. Multivariate analyses showed a strong association with current smoking in self-reported (odds ratio=4.16, 95% confidence interval [2.99-8.69]) and in medically assessed (odds ratio=12.55 [8.58-18.38]) populations. Association with body mass index was significant in medically assessed patients (odds ratio=1.12 [1.08-1.15]) for each increase of 1 U of BMI. LIMITATIONS: A causal relationship could not be established with such a cross-sectional study.
CONCLUSION: Hidradenitis suppurativa is a common disease, frequently associated with smoking and being overweight.

Entities:  

Mesh:

Year:  2008        PMID: 18674845     DOI: 10.1016/j.jaad.2008.06.020

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  106 in total

Review 1.  Hidradenitis Suppurativa: Causes, Features, and Current Treatments.

Authors:  Caroline Vinkel; Simon Francis Thomsen
Journal:  J Clin Aesthet Dermatol       Date:  2018-10-01

2.  The Burden of Hidradenitis Suppurativa in a Cohort of Patients in Southern Finland: A Pilot Study.

Authors:  Nicolas Kluger; Martta Ranta; Martina Serlachius
Journal:  Skin Appendage Disord       Date:  2017-01-12

3.  [Acne inversa].

Authors:  F G Bechara; W Hartschuh
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

4.  Comorbidities of hidradenitis suppurativa (acne inversa).

Authors:  Sabine Fimmel; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2010-01

Review 5.  [Hidradenitis suppurativa/acne inversa: An update].

Authors:  J Kirschke; S Hessam; F G Bechara
Journal:  Hautarzt       Date:  2015-06       Impact factor: 0.751

Review 6.  Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.

Authors:  Nicolò Scuderi; Ambra Monfrecola; Luca Andrea Dessy; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2017-03-21

7.  The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study.

Authors:  George Denny; Milan J Anadkat
Journal:  J Am Acad Dermatol       Date:  2016-09-28       Impact factor: 11.527

8.  Hair follicle stem cell replication stress drives IFI16/STING-dependent inflammation in hidradenitis suppurativa.

Authors:  Cindy Orvain; Yea-Lih Lin; Francette Jean-Louis; Hakim Hocini; Barbara Hersant; Yamina Bennasser; Nicolas Ortonne; Claire Hotz; Pierre Wolkenstein; Michele Boniotto; Pascaline Tisserand; Cécile Lefebvre; Jean-Daniel Lelièvre; Monsef Benkirane; Philippe Pasero; Yves Lévy; Sophie Hüe
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

9.  [Acne inversa (hidradenitis suppurativa). From diagnosis to therapy].

Authors:  M Mühlstädt; F G Bechara; C Kunte
Journal:  Hautarzt       Date:  2013-01       Impact factor: 0.751

10.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.